Synergistic effects of crizotinib and radiotherapy in experimental EML4-ALK fusion positive lung cancer

Radiotherapy and Oncology

Volumn 114, Issue 2, 2015, Pages 173-181

  Dai, Ying ^a,b   Wei, Quanxiang ^a,b   Schwager, Christian ^a,b   Moustafa, Mahmoud ^a,b,c   Zhou, Cheng ^a,b   Lipson, Kenneth E ^d   Weichert, Wilko ^a,e   Debus, Jürgen ^a,b   Abdollahi, Amir ^a,b  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^c Suez Canal University Faculty of Medicine   (Egypt)

^d FIBROGEN INC   (United States)

^e UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

ALK; Crizotinib; Non small cell lung cancer; Radiotherapy

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; CASPASE 3; CASPASE 7; CRIZOTINIB; SCATTER FACTOR RECEPTOR; EML4-ALK FUSION PROTEIN, HUMAN; ONCOPROTEIN; PROTEIN KINASE INHIBITOR; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE;

A549 CELL LINE; ANIMAL MODEL; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER RADIOTHERAPY; CANCER SIZE; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE MUTATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; ION THERAPY; LINEAR ENERGY TRANSFER; MONOTHERAPY; MOUSE; NON SMALL CELL LUNG CANCER; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RADIATION DOSE; RADIATION PROTECTION; TUMOR GROWTH; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; CARCINOMA, LEWIS LUNG; CARCINOMA, NON-SMALL-CELL LUNG; CHEMORADIOTHERAPY; DRUG EFFECTS; DRUG POTENTIATION; DRUG SCREENING; FEMALE; GENETICS; LUNG NEOPLASMS; METABOLISM; PATHOLOGY; RADIATION RESPONSE; RANDOMIZATION; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; CARCINOMA, LEWIS LUNG; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CHEMORADIOTHERAPY; DRUG SYNERGISM; FEMALE; HUMANS; LUNG NEOPLASMS; MICE; MICE, INBRED C57BL; ONCOGENE PROTEINS, FUSION; PROTEIN KINASE INHIBITORS; PYRAZOLES; PYRIDINES; RANDOM ALLOCATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84926199090     PISSN: 01678140     EISSN: 18790887     Source Type: Journal    
DOI: 10.1016/j.radonc.2014.12.009     Document Type: Article

References (31)

1. M.J. Lobo, A.S. Garden, and W. Morrison Post-operative external beam radiotherapy for differentiated thyroid cancer: modern era outcomes and morbidity Int J Radiat Oncol 72 2008 S396 S397
2. S.A. McAvoy, K.T. Ciura, and J.M. Rineer Feasibility of proton beam therapy for reirradiation of locoregionally recurrent non-small cell lung cancer Radiother Oncol 109 2013 38 44
3. W.Y. Shen, J. Ji, and Y.S. Zuo Comparison of efficacy for postoperative chemotherapy and concurrent radiochemotherapy in patients with IIIA-pN2 non-small cell lung cancer: an early closed randomized controlled trial Radiother Oncol 110 2014 120 125
4. M.M. van den Heuvel, W. Uyterlinde, and A.D. Vincent Additional weekly Cetuximab to concurrent chemoradiotherapy in locally advanced non-small cell lung carcinoma: efficacy and safety outcomes of a randomized, multi-center phase II study investigating Radiother Oncol 110 2014 126 131
5. S.I. Jalal, H.D. Riggs, and A. Melnyk Updated survival and outcomes for older adults with inoperable stage III non-small-cell lung cancer treated with cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel: analysis of a phase III trial from the Hoosier Oncology Group (HOG) and US Oncology Ann Oncol 23 2012 1730 1738
6. C. Billiet, H. Decaluwe, and S. Peeters Modern post-operative radiotherapy for stage III non-small cell lung cancer may improve local control and survival: a meta-analysis Radiother Oncol 110 2014 3 8
7. L. Horn, and W. Pao EML4-ALK: honing in on a new target in non-small-cell lung cancer J Clin Oncol 27 2009 4232 4235
8. A. Warth, R. Penzel, and H. Lindenmaier EGFR, KRAS, BRAF and ALK gene alterations in lung adenocarcinomas: patient outcome, interplay with morphology and immunophenotype Eur Respir J 43 2014 872 883
9. K. Inamura, K. Takeuchi, and Y. Togashi EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers J Thorac Oncol 3 2008 13 17
10. H.M. Amin, and R. Lai Pathobiology of ALK+ anaplastic large-cell lymphoma Blood 110 2007 2259 2267
11. T.R. Webb, J. Slavish, and R.E. George Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapy Expert Rev Anticancer Ther 9 2009 331 356
12. D.R. Camidge, Y. Bang, and E.L. Kwak Progression-free survival (PFS) from a phase I study of crizotinib (PF-02341066) in patients with ALK-positive non-small cell lung cancer (NSCLC) J Clin Oncol 29 2011
13. S.L. Timofeevski, M.A. McTigue, and K. Ryan Enzymatic characterization of c-MET receptor tyrosine kinase oncogenic mutants and kinetic studies with aminopyridine and triazolopyrazine inhibitors Biochemistry 48 2009 5339 5349
14. J.J. Cui, M. Tran-Dube, and H. Shen Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK) J Med Chem 54 2011 6342 6363
15. H.Y. Zou, Q. Li, and J.H. Lee An orally available small-molecule inhibitor of c-MET, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms Cancer Res 67 2007 4408 4417
16. S.H. Ou, E.L. Kwak, and C. Siwak-Tapp Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification J Thorac Oncol 6 2011 942 946
17. K. Bergethon, A.T. Shaw, and S.H. Ou ROS1 rearrangements define a unique molecular class of lung cancers J Clin Oncol 30 2012 863 870
18. J.K. Lennerz, E.L. Kwak, and A. Ackerman MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib J Clin Oncol 29 2011 4803 4810
19. F. De Bacco, P. Luraghi, and E. Medico Induction of MET by ionizing radiation and its role in radioresistance and invasive growth of cancer J Natl Cancer Inst 103 2011 645 661
20. A.T. Shaw, D.W. Kim, and K. Nakagawa Crizotinib versus chemotherapy in advanced ALK-positive lung cancer N Eng J Med 368 2013 2385 2394
21. M. Niklas, S. Greilich, and C. Melzig Engineering cell-fluorescent ion track hybrid detectors Radiat Oncol 8 2013 141
22. G.D. Sharungbam, C. Schwager, and S. Chiblak Identification of stable endogenous control genes for transcriptional profiling of photon, proton and carbon-ion irradiated cells Radiat Oncol 7 2012 70
23. S. Domhan, C. Schwager, and Q. Wei Deciphering the systems biology of mTOR inhibition by integrative transcriptome analysis Curr Pharm Des 20 2014 88 100
24. F. Kiessling, C. Fink, and M. Hansen Magnetic resonance imaging of nude mice with heterotransplanted high-grade squamous cell carcinomas - use of a low-loaded, covalently bound Gd-Hsa conjugate as contrast agent with high tumor affinity Invest Radiol 37 2002 193 198
25. G. Brix, W. Semmler, R. Port, L.R. Schad, G. Layer, and W.J. Lorenz Pharmacokinetic parameters in CNS Gd-Dtpa enhanced MR imaging J Comput Assist Tomogr 15 1991 621 628
26. J.P. Koivunen, C. Mermel, and K. Zejnullahu EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer Clin Cancer Res 14 2008 4275 4283
27. V. Tumati, S. Kumar, L. Yu, B. Chen, H. Choy, and D. Saha Effect of PF-02341066 and radiation on non-small cell lung cancer cells Oncol Rep 29 2013 1094 1100
28. Y. Sun, K.A. Nowak, and N.G. Zaorsky ALK inhibitor PF02341066 (crizotinib) increases sensitivity to radiation in non-small cell lung cancer expressing EML4-ALK Mol Cancer Ther 12 2013 696 704
29. A.J. Weickhardt, B. Scheier, and J.M. Burke Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer J Thorac Oncol 7 2012 1807 1814
30. T. Miyamoto, M. Baba, and T. Sugane Carbon ion radiotherapy for stage I non-small cell lung cancer using a regimen of four fractions during 1 week J Thorac Oncol 2 2007 916 926
31. T. Miyamoto, N. Yamamoto, and H. Nishimura Carbon ion radiotherapy for stage I non-small cell lung cancer Radiother Oncol 66 2003 127 140